News and Insights
Transparency Around Value to Support Rational Pricing Discussions
The issue of drug pricing has become a staple of the news cycle, with fresh headlines every few weeks spotlighting either the high cost of new breakthrough drugs like Sovaldi, or jaw-dropping price hikes for existing, popular products like the EpiPen. While these examples represent two very different sets of issues, in the minds of consumers, they boil down to the same thing: drugs cost too much, and drug companies are to blame. And the only framework for a rational discussion of the subject rests on a transparent, data-based value case for the product in question.
Much of the public sensitivity to drug pricing is a function of growing consumer exposure to healthcare costs. Payers and employers are shifting more of the financial burden onto patients in the form of higher deductibles, copays, and premiums. Consumers don’t need to be hospitalized to experience drug price increases; they feel it every time they fill a prescription.
So the focus on drug pricing is not likely to go away without meaningful change. The federal government’s recently released blueprint for addressing drug prices, American Patients First, proposes a comprehensive plan for lowering consumer drug costs.1 However, the ultimate impact depends on the details of implementation, and in any case, could take years.
In the meantime, what payers, patients and policymakers really want to know is the answer to one question – why does the drug cost this much?Read More
Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.
Whether you need a new plan or a second opinion, Numerof has the insight you're looking for.